Palisade Bio (NASDAQ: PALI), a clinical-stage biopharmaceutical company, has announced the pricing of an upsized $120 million underwritten public offering. The offering consists of 171,440,559 shares of common stock priced at $0.70 per share.
The company has granted underwriters a 45-day option to purchase up to an additional 25,714,285 shares at the public offering price. Ladenburg Thalmann & Co. Inc. is serving as the sole book-running manager. The offering is expected to close around October 2, 2025, subject to customary closing conditions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.